Thyas Co. Ltd. (“Thyas”; Kyoto, Japan; Representative Directors, Yasumichi Hitoshi and Ryosuke Gonotsubo) announces that its project is adopted for the Cyclic Innovation for Clinical Empowerment (“CiCLE”) program of Japan Agency for Medical Research and Development (“AMED”), in which Thyas will conduct world’s first clinical trial of iPS Cell (“iPSC”)-derived Cytotoxic T Lymphocyte (“CTL” or “killer T Cell”) with a grant up to $7.2 million (JPY 950 million) from AMED.

Click here for more details.